MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Interventional Mitral Annular Reduction Techniques
International experience with the Carillon, Mitralign, and CardioBand mitral annuloplasty devices.
By Robert Schueler, MD, and Georg Nickenig, MD
Perspectives on Transcatheter Mitral Therapy
Comparing devices and methods for the treatment of mitral valve regurgitation.
By Marcel Weber, MD; Johanna Vogelhuber, MD; Can Öztürk, MD; Sebastian Zimmer, MD; and Georg Nickenig, MD
Pilot European Sentinel Registry Supports Transcatheter Mitral Valve Repair
August 27, 2014—Georg Nickenig, MD, et al published in-hospital results and 1-year follow-up of 628 patients with mitral regurgitation (MR) undergoing transcatheter mitral valve repair (TMVR) in the 2011–2012 Pilot European Sentinel Registry in the Journal of the American College of Cardiology (2014;64:875–884). The aim of this multinational registry is to present a real-world overview of TMVR use in Europe.
Mitralign Annuloplasty FIM Study Published
June 21, 2016—Findings from the Mitralign percutaneous annuloplasty first-in-man study were published by Georg Nickenig, MD, et al in the Journal of the American College of Cardiology (JACC; 2016;67:2927–2936).
FORWARD Clinical Study Begins for Medtronic's Evolut R TAVR System in Real-World Setting
March 7, 2016—Medtronic plc announced that Prof.
TRI-REPAIR Study Evaluates Edwards' Cardioband System at 6 Months
April 15, 2019—Data from the TRI-REPAIR study evaluating the safety and performance of tricuspid regurgitation (TR) repair with the Cardioband transcatheter tricuspid valve reconstruction system (Edwards Lifesciences) were published by Georg Nickenig, MD, et al in Journal of the American College of Cardiology (JACC; 2019;73:1905–1915).
Mitralign Percutaneous Annuloplasty System Shows Improved Valve Function at 6 Months
June 1, 2015—Mitralign Inc. announced that 6-month data on the Mitralign percutaneous annuloplasty system (MPAS) for the treatment of functional mitral regurgitation (FMR) were presented by Prof.
Data to Be Presented for Valtech Cardio's Cardioband Annuloplasty System
March 9, 2015—Valtech Cardio, Ltd. announced that it will present updated results of its multicenter feasibility study of the Cardioband annuloplasty system at ACC.15, the American College of Cardiology scientific sessions being held March 14–16, 2015 in San Diego, California.
Enrollment Completed in EU Study of Mitralign System for Functional Mitral Regurgitation
April 8, 2014—Mitralign, Inc. (Tewksbury, MA) announced that it has completed enrollment in a European study investigating the Mitralign system to treat functional mitral regurgitation (MR).
Mitralign's MPAS Approved in Europe to Treat Functional Mitral Regurgitation
February 22, 2016—Mitralign, Inc. announced that the Mitralign percutaneous annuloplasty system (MPAS) has received European CE Mark approval for the treatment of functional mitral regurgitation (FMR).
Abbott's TriClip Receives CE Mark Approval for Transcatheter Tricuspid Valve Repair
April 9, 2020—Abbott announced that its TriClip transcatheter tricuspid valve repair system has received European CE Mark approval as a nonsurgical treatment for tricuspid regurgitation (TR) in Europe and countries that recognize the CE Mark.
First-in-Human Implantation Performed With MValve's Transapical Mitral Valve Replacement System
October 5, 2015—MValve Technologies Ltd. announced the first-in-human implantation of its catheter-based transapical mitral valve replacement system.
Edwards' Cardioband Tricuspid System Granted CE Mark Approval
April 30, 2018—Edwards Lifesciences announced that it has received European CE Mark approval for its Cardioband tricuspid valve reconstruction system for the treatment of tricuspid regurgitation.
TRILUMINATE Trial Begins for Abbott Vascular's Transcatheter Tricuspid Valve Repair System
August 11, 2017—Abbott Vascular announced that the first patient has been enrolled in the TRILUMINATE clinical study to evaluate the company's clip-based transcatheter tricuspid valve repair (TTVR) system for treating patients with moderate or severe tricuspid regurgitation.
One-Year Data Support Valtech's Cardioband Mitral Valve Reconstruction System
May 31, 2016—One-year follow-up results of a European study of the Cardioband mitral value reconstruction system (Valtech Cardio, Ltd.) were presented at the EuroPCR 2016 conference held May 17–20 in Paris, France.
TRILUMINATE Study Evaluates Abbott's Tricuspid Valve Repair System
May 21, 2019—Abbott announced data from its TRILUMINATE study of the company's minimally invasive tricuspid valve repair system.
Six-Month Data From TRILUMINATE Feasibility Study Presented for Abbott's TriClip Device
September 28, 2019—Abbott announced new data from the TRILUMINATE Feasibility Study were presented at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, held September 25–29 in San Francisco, California.
Assessing Tricuspid and Mitral Interventions
By Rebecca T. Hahn, MD; Didier Tchétché, MD; and Dominick Angiolillo, MD
Abbott’s MitraClip and TriClip Devices Evaluated in Late-Breaking Data for Mitral and Tricuspid Regurgitation
June 8, 2022—Abbott announced late-breaking data for the MitraClip transcatheter edge-to-edge repair (TEER) device and the TriClip minimally invasive tricuspid heart valve repair device.
An Interview With Ulrich Schäfer, MD
Prof. Schäfer shares updates on the current status of therapies for each of the four heart valves, as well as new technologies to address heart failure and more.
